By the same authors

Targeting gene therapy for prostate cancer

Research output: Contribution to journalLiterature review

Author(s)

Department/unit(s)

Publication details

JournalCurrent pharmaceutical design
DatePublished - 2004
Issue number5
Volume10
Number of pages25
Pages (from-to)531-555
Original languageEnglish

Abstract

Gene therapy is rapidly emerging as a viable clinical strategy to treat prostate cancer. New developments, such as targeted expression of therapeutic genes, and viruses that are designed to selectively replicate in prostate cancer cells have led to vectors with improved safety, even in elderly male patients. This review describes the various different viral and non-viral strategies employed to date, with a summary of current clinical trials. The main focus of the review is a discussion of the need, and the potential methods that can be used for targeted expression of the therapeutic gene specifically to prostate tumours and metastases. This includes methods of abrogating vector transduction of non-specific tissues, enhancement of transduction into prostate tumour tissue, transcriptional control of the therapeutic gene and some examples of prostate cancer-specific therapeutic genes. We also consider the future of prostate cancer gene therapy and the factors that should be taken into account when designing clinical trials, in a field that is expected to impact on clinical management of a common turnout type.

    Research areas

  • prostate cancer, gene therapy, virus vectors, tissue specificity, STEM-CELL ANTIGEN, TISSUE-SPECIFIC EXPRESSION, ADENOVIRUS-MEDIATED EXPRESSION, ANDROGEN-DEPRIVATION THERAPY, GLANDULAR KALLIKREIN 2, THYMIDINE KINASE GENE, ANTISENSE BCL-2 OLIGODEOXYNUCLEOTIDES, RECOMBINANT ADENOASSOCIATED VIRUS, TRANSMEMBRANE SERINE-PROTEASE, LEWIS CARBOHYDRATE ANTIGENS

Projects

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations